(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl heptanoate

Catalog No. :
ACHFAK225
CAS No. :
4956-37-0
Molecular Formula :
C25H36O3
Molecular Weight :
384.56

IUPAC Name:(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl heptanoate

(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl heptanoate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl heptanoate
IUPAC Name(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl heptanoate
Molecular FormulaC25H36O3
Molecular Weight384.56
SMILESCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O)=CC=C4[C@H]3CC[C@]12C
InChI KeyRFWTZQAOOLFXAY-BZDYCCQFSA-N
Synonymoestradiol 17-heptanoate;estra-1,3,5(10)-triene-3,17b-diol 17-heptanoate;ESTRADIOL 17-HEPTANOATE;ESTRADIOL ENANTHATE;BETA-ESTRADIOL-17-ENANTHATE;B-estradiol 17-enanthate;estra-1,3,5(10)-triene-3,17beta-diol 17-heptanoate;Estradiol enantate
CAS No.4956-37-0

Synthetic Route by SureRoute

1. ACHFAK225 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACAHDT572 route compound structure diagram
    ACAHDT57210051-45-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACHFAK225 route product structure diagram
    ACHFAK2254956-37-0
Inquiry

2. ACHFAK225 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACHFAK225 route product structure diagram
    ACHFAK2254956-37-0
Inquiry

Comments (0)